Skip to content

Labor Induction and Maternal BMI, Comparison of Different Pre-induction Cervical Ripening Methods

Labor Induction and Maternal BMI: Comparison of Different Pre-induction Cervical Ripening Methods: The Cook Double Balloon Catheter vs PGE1 Tablets in Lean, Overweight, and Obese Women. A Prospective Randomized Study.

Status
UNKNOWN
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02223949
Enrollment
624
Registered
2014-08-22
Start date
2014-10-31
Completion date
2016-11-30
Last updated
2014-08-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Labor Complications, Obesity

Keywords

Obesity, Labor complications, Induction of labor, Mechanical cervical ripening

Brief summary

The purpose of this study is to investigate whether mechanical cervical ripening (using the Cook double balloon catheter) is superior or inferior to pharmacological agents (PGE1) in overweight and obese women undergoing labor induction.

Interventions

Sponsors

Hillel Yaffe Medical Center
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* Age 18 years of age or older. * Diagnosed to be pregnant (al least 37 weeks of gestation) with a medical indication for labor induction, including: postdate pregnancy, preeclampsia, gestational or chronic hypertension, Gestational Diabetes Mellitus at term, Oligohydramnios, Polyhydramnios, fetal growth restriction, maternal background disease necessitating delivery, Isoimmunisation, maternal Thrombophilia, intrahepatic cholestasis of pregnancy. * Having a Bishop score of 4 points or less. * Diagnosed as having singleton pregnancy at term (37 weeks at least) in a vertex presentation, with intact membranes, and absence of significant regular uterine contraction. * Willingness to comply with the protocol for the duration of the study. * Has agreed and signed an informed consent after given oral and written explanation.

Exclusion criteria

* Anay contraindication for a vaginal delivery (i.e. placenta previa, non vertex presentation, estimated fetal weight of less than 4500 gr). * Ruptured membranes. * Previous cesarian section or presence of any uterine scar. * Documented labor with four or more spontanous uterine contractions per hour. * Suspected fetal distress necessitating immediate intervention. * Proven malignancy of the cervix. * Active vaginal bleeding. * Active inflammatory or purulent condition of the lower genital tract. * Active asthma.

Design outcomes

Primary

MeasureTime frame
Cesarian section rate24 hours

Secondary

MeasureTime frameDescription
Incidence of excessive uterine activity Incidence of excessive uterine activity24 hoursAt least 6 uterine contractions per 10- minutes period, or hyperstimulation, if combined with fetal heart rate abnormalities, or hypertonus defined as single contraction of 2-minute duration.
Active labor onset24 hours
Treatment failure12-24 hoursProportion of subjects with unfavorable/unchanged Bishop score 12-24 hours after ripening
The ripening-to-delivery time interval24 hours
Need for oxytocin induction and/or augmentation of labor24 hours
Proportion of vaginal delivery24 hours
Intra-partum or postpartum fever48 hours
Incidence of meconium staining24 hours
The proportion of neonates with 5-minute Apgar scores of less than 748 hours
The number of neonates who were admitted to the neonatal intensive care unit48 hours
morbidity and mortality48 hoursNumber of cases of serious maternal and/or neonatal morbidity or death (including uterine rupture, maternal admission to the intensive care unit, maternal septicemia, placental abruption, hemorrhage at required blood transfusion, hysterectomy, neonatal seizures, birth asphyxia, meconium aspiration syndrome, or neonatal sepsis).
Mode of delivery24 hoursNVD vs. instrumental

Countries

Israel

Contacts

Primary ContactSaja Murra Anabosy, MD
saja83@gmail.com+972 50 9260067
Backup ContactAsnat Walfisch, MD
asnatwalfisch@yahoo.com+972 50 4492200

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026